UBC was pleased to connect with so many industry colleagues at DIA 2019. We look forward to continuing the conversation on important clinical development and safety developments.
April 24, 20254 min read
UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025
UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.